anxiety/nausea

BACKGROUND OF THE INVENTION This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and

The present invention relates to a method of treatment of emesis, such as cytotoxic agent or radiation induced nausea and vomiting or motion sickness; anxiety; and irritable bowel syndrome (IBS); in mammals including humans, and to the use of compounds in the preparation of a medicament for the

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or dependence; pain; gastric stasis; gastric dysfunction (such as occurs

This invention relates to a class of spirocyclic compounds which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or dependence; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with

This invention relates to indole derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which are potent and selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT receptors of

This invention relates to heterocyclic compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which act upon 5-hydroxytryptamine (5-HT) receptors of the type located on terminals of

This invention relates to tetracyclic ketones, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which are potent and selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT receptors of

This invention relates to lactam derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which are potent and selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT receptors of

This invention relates to ketone derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to ketone derivatives which are potent and selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT

This invention relates to ketone derivatives to processes for theIr preparation to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to ketone derivative a which are potent and selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT

This invention relates to lactam derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which are potent and selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT receptors of

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with

This application claims the benefit of Provisional Application 60/069,890 Jan. 5, 1996. The present invention is directed to certain novel compounds and their use as pharmaceutical agents having unique central nervous system activity. This invention relates to 4,5-dihydronaphth[1,2-c]isoxazoles and

CROSS-REFERENCE TO RELATED APPLICATION This application claims, under 35 U.S.C. .sctn.119(a), the benefit of Korean Patent Application No. 10-2007-0084322 filed Aug. 22, 2007, the entire contents of which are incorporated herein by reference. BACKGROUND OF THE INVENTION 1. Field of the Invention The